Suppr超能文献

探索结核分枝杆菌核糖体蛋白 S1 中临床突变体 T370P 和 W403G 的吡嗪酰胺耐药机制。

Exploring the Pyrazinamide Drug Resistance Mechanism of Clinical Mutants T370P and W403G in Ribosomal Protein S1 of Mycobacterium tuberculosis.

机构信息

State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, National Experimental Teaching Center for Life Sciences and Biotechnology, School of Life Sciences and Biotechnology , Shanghai Jiao Tong University , Shanghai , 200240 , China.

Department of Biotechnology , Abdul Wali Khan University Marden , Mardan 23200 , Pakistan.

出版信息

J Chem Inf Model. 2019 Apr 22;59(4):1584-1597. doi: 10.1021/acs.jcim.8b00956. Epub 2019 Mar 12.

Abstract

Pyrazinamide (PZA) is an essential first line antitubercular drug, which plays a crucial role in tuberculosis treatment. The PZA, which is considered as a pro-drug needs an enzyme of mycobacterial pyrazinamidase (PZase) for its conversion into an active form pyrazinoic acid. Further, this active form of PZA inhibits the ribosomal proteins S1, which facilitates the transfer-mRNA complex formation throughout the translation. The spontaneous mutations in RpsA have been found to be associated with PZA drug resistance. However, the drug resistance mechanism is still unclear. Furthermore, there is no such information available about the structural dynamics of RpsA protein because of mutations that confer Pyrazinoic acid resistance. Moreover, a total of 18 clinical PZA-resistant isolates were investigated and found to be pncA, which allowed exploration of the resistance mechanism of RpsA in the mutated state. Samples were repeated for the drug susceptibility testing followed by RpsA gene sequencing. A total of 11 clinical isolates harbored a total of 15 mutations. Almost half of the total strains (7/15) were observed to be in the conserved region of RpsA and known as Mycobacterium tuberculosis C-terminal domain. In the current study, (2/7) mutation T370P (mutant 1) and W403G (mutant 2) were explored to ensure the RpsA resistance mechanism through essential dynamics simulation. The essential dynamics study results revealed that the distal loop mutations drastically altered the conformation of RpsA both in the absence (-) and presence (+) of pyrazinoic acid drug for two reasons: (1) dramatic alteration or reduction in the binding pattern of pyrazinoic acid with active site residues observed and (2) a clear image of the opening and closing switching mechanism was seen upon the distal site mutation on nearby 3-helixes beside the pyrazinoic acid binding site. This switch was found to consistently remain closed only in wild type systems, while it was open in the mutant systems. We called such distance impact an "allosteric effect." The overall mechanistic investigations will provide useful information behind drug resistance for better understanding to manage tuberculosis.

摘要

吡嗪酰胺(PZA)是一种重要的一线抗结核药物,在结核病治疗中起着至关重要的作用。吡嗪酰胺被认为是一种前体药物,需要分枝杆菌吡嗪酰胺酶(PZase)的酶将其转化为活性形式吡嗪酸。此外,这种活性形式的 PZA 抑制核糖体蛋白 S1,从而促进核糖体转移-mRNA 复合物的形成,完成翻译。已经发现 RpsA 的自发突变与 PZA 耐药性有关。然而,耐药机制尚不清楚。此外,由于赋予吡嗪酸耐药性的突变,关于 RpsA 蛋白的结构动力学尚无此类信息。此外,共研究了 18 个临床 PZA 耐药分离株,发现均为 pncA,这使得可以在突变状态下探索 RpsA 的耐药机制。对耐药性进行了药物敏感性测试和 RpsA 基因测序。总共 11 个临床分离株总共携带了 15 个突变。几乎一半的总菌株(7/15)位于 RpsA 的保守区域,称为结核分枝杆菌 C 端结构域。在本研究中,(2/7)突变 T370P(突变体 1)和 W403G(突变体 2)被探索以通过基本动力学模拟确保 RpsA 耐药机制。基本动力学研究结果表明,在缺乏(-)和存在(+)吡嗪酸药物的情况下,远端环突变使 RpsA 的构象发生了巨大变化,原因有二:(1)观察到活性位点残基与吡嗪酸的结合模式发生了剧烈改变或减少,(2)在吡嗪酸结合位点附近的 3 螺旋上的远端位点突变后,看到了打开和关闭切换机制的清晰图像。这种开关在野生型系统中始终保持关闭状态,而在突变系统中则保持打开状态。我们称这种距离影响为“别构效应”。总体机制研究将为更好地理解结核病管理提供耐药背后的有用信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验